Article

Calcium Channel Blockers: clinical outcome associations with reported pharmacogenetics variants in 32,000 patients

2022-03-23

Abstract excerpt

<h4>Background</h4> Dihydropiridine calcium channel blockers (dCCB) (e.g. amlodipine) are widely used for treating hypertension. Pharmacogenetic variants impact treatment efficacy, yet evidence on clinical outcomes in routine primary care is limited. We aimed to estimate associations between reported pharmacogenetic variants and incident adverse events in a community-based cohort prescribed dCCB, including in high...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f7daa9ba-bbe0-5246-8764-02e5ace0b4d4
DOI: 10.1101/2022.03.23.22272805

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Calcium Channel Blockers: clinical outcome associations with reported pharmacogenetics variants in 32,000 patientsDOI 10.1101/2022.03.23.22272805Read

Combining pharmacogenetics and patient characteristic polygenic scores to improve outcome prediction for Calcium Channel Blocker treatmentSemantic proximity Read

Genetic variants related to antihypertensive targets inform drug efficacy and side effectsSemantic proximity Read

RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment.Semantic proximity Read

Use of Genetic Variants Related to Antihypertensive Drugs to Inform on Efficacy and Side EffectsSemantic proximity Read

Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies.Semantic proximity Read

Calcium channel blockers as drug repurposing candidates for gestational diabetes: Mining large scale genomic and electronic health records data to repurpose medications.Semantic proximity Read

Using genetics to assess the association of commonly used antihypertensive drugs with diabetes, glycaemic traits and lipids: a trans-ancestry Mendelian randomisation studySemantic proximity Read

Leveraging large-scale biobank EHRs to enhance pharmacogenetics of cardiometabolic disease medicationsSemantic proximity Read

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy.Semantic proximity Read

[Cardiovascular pharmacogenomics].Semantic proximity Read

Resistant Hypertension Variants Link to Hyperaldosteronism and Potassium Levels.Semantic proximity Read

Pharmacogenetic factors affecting β-blocker metabolism and response.Semantic proximity Read